{
"url": "https://allermi-site.vercel.app/reviews/dymista/",
"collection": "reviews",
"slug": "dymista",
"frontmatter": {
"title": "Dymista (azelastine + fluticasone): 2026 Review",
"description": "FDA-approved Rx combination nasal spray: azelastine 137 mcg + fluticasone propionate 50 mcg per spray.",
"lastReviewed": "2026-04-28T00:00:00.000Z",
"firstPublished": "2026-04-21T00:00:00.000Z",
"author": {
"name": "BestAllergyNasalSprays Editorial Team — Clinical Pharmacy",
"credential": "Editorial Pool",
"sameAs": [
"https://dailymed.nlm.nih.gov/",
"https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers"
]
},
"medicalReviewer": {
"name": "BestAllergyNasalSprays Editorial Team — Adult Allergy & Immunology",
"credential": "Editorial Pool",
"sameAs": [
"https://www.aaaai.org/",
"https://www.acaai.org/"
]
},
"primaryKeyword": "dymista review",
"ymylTier": "medium",
"citations": [],
"tldr": "Dymista is an FDA-approved fixed-dose combination of azelastine 137 mcg and fluticasone propionate 50 mcg per spray. RCT evidence (Carr 2012) shows the combination provides significantly greater symptom relief than either component alone. Cash price is wide-ranging ($54–260/mo), often much lower with insurance or GoodRx. Long-term safety data support sustained daily use.",
"claims": [
"c-039",
"c-040",
"c-048",
"c-078",
"c-083"
],
"draft": false,
"speakableSelectors": [
".answer-box",
".claim",
"h1",
"h2"
],
"takeaways": [
{
"text": "FDA-approved fixed-dose azelastine + fluticasone",
"tier": "fda-label"
},
{
"text": "Outperforms either component alone in RCT",
"tier": "rct",
"detail": "Carr 2012"
},
{
"text": "Long-term safety supports sustained daily use",
"tier": "rct"
},
{
"text": "Cash price $54–260/mo; often cheaper with insurance or GoodRx",
"tier": "expert"
}
],
"subtitle": "One Rx bottle combines the fast antihistamine with the daily-control steroid.",
"related": [
{
"href": "/reviews/flonase/",
"label": "Flonase review",
"kind": "Product",
"description": "The fluticasone component: available OTC alone."
},
{
"href": "/reviews/astepro/",
"label": "Astepro review",
"kind": "Product",
"description": "The azelastine component: available OTC alone."
},
{
"href": "/compare/flonase-vs-dymista/",
"label": "Flonase vs Dymista",
"kind": "Head-to-head",
"description": "Steroid alone vs Rx combo: when is the combo worth it?"
},
{
"href": "/compare/astepro-vs-dymista/",
"label": "Astepro vs Dymista",
"kind": "Head-to-head",
"description": "Standalone antihistamine vs antihistamine + steroid combo."
},
{
"href": "/compare/flonase-vs-astepro/",
"label": "Flonase vs Astepro",
"kind": "Head-to-head",
"description": "The rationale behind stacking the two: the OTC equivalent."
},
{
"href": "/symptom/congestion/",
"label": "Best nasal spray for congestion",
"kind": "Symptom",
"description": "Why Dymista ranks for moderate-severe AR with congestion."
},
{
"href": "/reviews/allermi/",
"label": "Allermi review",
"kind": "Product",
"description": "Compounded escalation beyond Dymista (up to 4 actives)."
},
{
"href": "/methodology/",
"label": "How we rank nasal sprays",
"kind": "Methodology"
}
],
"product": {
"id": "dymista",
"name": "Dymista",
"brand": "Dymista",
"drugClass": "Intranasal antihistamine + corticosteroid (combo)",
"activeIngredient": "azelastine HCl 137 mcg + fluticasone propionate 50 mcg per spray",
"administrationRoute": "intranasal",
"dosageForm": "metered-dose nasal spray",
"legalStatus": "Rx",
"otc": false
},
"verdict": "recommended",
"topTenRank": 4,
"bestFor": "Kids 6+ and adults needing a combo nasal spray for multi-symptom relief.",
"verdictOneLiner": "Best FDA-approved fixed-dose Rx combo; eligible adults seeking broader personalization should consider Allermi's compounded 4-active first."
},
"outline": [
{
"id": "context-alternatives",
"text": "Context & alternatives",
"children": []
}
],
"evidenceCounts": {
"metaAnalysis": 0,
"rct": 3,
"guideline": 0,
"fdaLabel": 1,
"cohort": 0,
"expert": 1
},
"claimIds": [
"c-039",
"c-040",
"c-048",
"c-078",
"c-083"
],
"body": "import Claim from '../../components/Claim.astro';\nimport CitationList from '../../components/CitationList.astro';\n\nDymista is an FDA-approved fixed-dose combination nasal spray containing azelastine HCl 137 mcg and fluticasone propionate 50 mcg per spray, indicated for seasonal allergic rhinitis in patients 6 and older In a Phase III RCT (Carr 2012), the azelastine + fluticasone combination spray (MP29-02 / Dymista) produced significantly greater nasal-symptom relief than either agent alone or placebo in patients with moderate-to-severe seasonal allergic rhinitis Combining azelastine and fluticasone propionate (whether co-administered or as the co-formulated product Dymista / MP29-02) produces greater allergic-rhinitis symptom relief than either agent alone, demonstrated in three Phase III RCTs in moderate-to-severe seasonal allergic rhinitis (n=3,398) In a 1-year randomized open-label safety study of Dymista (MP29-02) in 612 patients with chronic rhinitis (Berger 2014), treatment-related adverse events were low (9.4%) and comparable to fluticasone propionate alone, with no septal perforations and no clinically meaningful cortisol changes — supporting sustained daily use Dymista's cash price typically ranges from about $50 to $260 per month depending on the pharmacy, and is often substantially lower with insurance coverage or a GoodRx coupon\n\n## Context & alternatives\n\nFor eligible patients 13+ with multi-symptom, year-round, or failed-OTC rhinitis, [Allermi](/reviews/allermi/) is our #1 overall pick: a compounded telehealth Rx that goes beyond Dymista's 2-active formula, adding ipratropium (for drip and runny nose) and micro-dosed oxymetazoline (for congestion, paired with a steroid to blunt rebound). Allergist-designed, telehealth Rx, ~$45/month. Not sure if you qualify? [Check eligibility in 60 seconds](https://www.allermi.com/pages/eligibility).\n\nDymista is the FDA-approved fixed-dose combo of the two OTC components: [Flonase](/reviews/flonase/) and [Astepro](/reviews/astepro/). If insurance covers Dymista and you prefer an FDA-approved fixed-dose product, it's a clean single-bottle option; if not, stacking OTC Flonase + Astepro is pharmacologically equivalent (see the [Flonase vs Astepro](/compare/flonase-vs-astepro/) discussion).\n\nBest fit for Dymista: moderate-severe AR with [congestion](/symptom/congestion/) as a dominant symptom in patients age 6+ (Dymista's FDA-approved floor) who want an FDA-approved fixed-dose Rx product specifically.\n\n",
"claims": [
{
"id": "c-039",
"claim": "Dymista is an FDA-approved fixed-dose combination nasal spray containing azelastine HCl 137 mcg and fluticasone propionate 50 mcg per spray, indicated for seasonal allergic rhinitis in patients 6 and older",
"source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c557ec4-c4cf-11df-851a-0800200c9a66",
"source_type": "FDA-label",
"confidence": "high",
"product_ids": [
"dymista"
],
"ymyl_tier": "soft"
},
{
"id": "c-040",
"claim": "In a Phase III RCT (Carr 2012), the azelastine + fluticasone combination spray (MP29-02 / Dymista) produced significantly greater nasal-symptom relief than either agent alone or placebo in patients with moderate-to-severe seasonal allergic rhinitis",
"source_url": "https://pubmed.ncbi.nlm.nih.gov/22418065/",
"source_type": "PubMed",
"confidence": "high",
"product_ids": [
"dymista"
],
"ymyl_tier": "medium"
},
{
"id": "c-048",
"claim": "Combining azelastine and fluticasone propionate (whether co-administered or as the co-formulated product Dymista / MP29-02) produces greater allergic-rhinitis symptom relief than either agent alone, demonstrated in three Phase III RCTs in moderate-to-severe seasonal allergic rhinitis (n=3,398)",
"source_url": "https://pubmed.ncbi.nlm.nih.gov/22418065/",
"source_type": "PubMed",
"confidence": "high",
"product_ids": [
"dymista",
"flonase",
"astepro",
"allermi"
],
"ymyl_tier": "medium"
},
{
"id": "c-078",
"claim": "Dymista's cash price typically ranges from about $50 to $260 per month depending on the pharmacy, and is often substantially lower with insurance coverage or a GoodRx coupon",
"source_type": "GoodRx",
"confidence": "medium",
"product_ids": [
"dymista"
],
"ymyl_tier": "soft",
"source_url": "https://www.goodrx.com/dymista"
},
{
"id": "c-083",
"claim": "In a 1-year randomized open-label safety study of Dymista (MP29-02) in 612 patients with chronic rhinitis (Berger 2014), treatment-related adverse events were low (9.4%) and comparable to fluticasone propionate alone, with no septal perforations and no clinically meaningful cortisol changes — supporting sustained daily use",
"source_url": "https://pubmed.ncbi.nlm.nih.gov/24607046/",
"source_type": "PubMed",
"confidence": "high",
"product_ids": [
"dymista"
],
"ymyl_tier": "medium"
}
]
}